Neutropenic enterocolitis (typhlitis): Difference between revisions

 
(14 intermediate revisions by 5 users not shown)
Line 1: Line 1:
==Background==
==Background==
*Necrosis of bowel wall 2/2 polymicrobial invasion
*Necrosis of bowel wall secondary to polymicrobial invasion
**Involves terminal ileum and colon
**Involves terminal ileum and colon
**May progress to full-thickness infarction/perforation
**May progress to full-thickness infarction/perforation
*Occurs 10-14d after cytotoxic therapy


==Clinical Presentation==
==Clinical Features==
*Fever
*Typically presents 10-14d after cytotoxic therapy
*RLQ pain
*[[neutropenic fever|Fever]]
*Nausea
*[[RLQ pain]]
*Vomiting
*[[Nausea/vomiting]]


==Differential Diagnosis==
==Differential Diagnosis==
{{Oncologic emergencies DDX}}
{{Oncologic emergencies DDX}}
{{Abd DDX RLQ}}


==Diagnosis==
==Evaluation==
===Workup===
===Workup<ref>Machado NO. Neutropenic enterocolitis: A continuing medical and surgical challenge. N Am J Med Sci. 2010 Jul; 2(7): 293–300.</ref>===
CT A/P: cecal distention and wall thickening
*CBC with [[neutropenia]], [[thrombocytopenia]]
*Blood cultures positive in ~25-85%, frequently bowel organisms
*CT A/P: cecal distention, wall thickening, pneumatosis intestinalis, intestinal perforation, fat stranding
*Avoid endoscopic evaluation due to risk of perforation, hemorrhage, bacterial translocation, worsening sepsis


==Treatment==
==Management==
#Bowel rest
*Bowel rest
#NG suction
*[[NG tube]] to suction
#IVF
*[[IVF]]
#Broad spec abx
*TPN
*Consider G-CSF, particularly neutropenia < 100/ml and severe disease<ref>Greil R, Psenak O, Roila F. ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol. 2008;19(suppl 2:ii):116–1118.</ref>
*Broad spectrum antimicrobials, in particular against gut microbiota to include<ref>Gorschluter M, Mey U, Strehl J, Zinske C, Schepke M, Schmid F, Wolf IG, Sauerbruch T, Glasmacher A, et al. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol. 2005;75(1):1–13.</ref>:
**[[Metronidazole]] plus [[cefepime]]
**[[Piperacillin-tazobactam]]
**[[Amphotericin B]] when patient remains febrile, neutropenic for greater than 5 days despite broad spectrum antibiotics
*Surgical consult (possible need for right hemicolectomy)<ref>Williams N, Scott AD. Neutropaenic enterocolitis : a continuing surgical challenge. Br J Surg. 1997;84(9):1200–1205.</ref>


==Disposition==
==Disposition==
*Surgial consult (poss right hemicolectomy)
*Admit
 
==See Also==
*[[Neutropenic fever]]
 
==References==
<references/>


[[Category:GI]]
[[Category:GI]]
[[Category:ID]]
[[Category:ID]]
[[category:Surgery]]
[[Category:Heme/Onc]]

Latest revision as of 21:51, 29 October 2019

Background

  • Necrosis of bowel wall secondary to polymicrobial invasion
    • Involves terminal ileum and colon
    • May progress to full-thickness infarction/perforation

Clinical Features

Differential Diagnosis

Oncologic Emergencies

Related to Local Tumor Effects

Related to Biochemical Derangement

Related to Hematologic Derangement

Related to Therapy

RLQ Pain

Evaluation

Workup[1]

  • CBC with neutropenia, thrombocytopenia
  • Blood cultures positive in ~25-85%, frequently bowel organisms
  • CT A/P: cecal distention, wall thickening, pneumatosis intestinalis, intestinal perforation, fat stranding
  • Avoid endoscopic evaluation due to risk of perforation, hemorrhage, bacterial translocation, worsening sepsis

Management

  • Bowel rest
  • NG tube to suction
  • IVF
  • TPN
  • Consider G-CSF, particularly neutropenia < 100/ml and severe disease[2]
  • Broad spectrum antimicrobials, in particular against gut microbiota to include[3]:
  • Surgical consult (possible need for right hemicolectomy)[4]

Disposition

  • Admit

See Also

References

  1. Machado NO. Neutropenic enterocolitis: A continuing medical and surgical challenge. N Am J Med Sci. 2010 Jul; 2(7): 293–300.
  2. Greil R, Psenak O, Roila F. ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol. 2008;19(suppl 2:ii):116–1118.
  3. Gorschluter M, Mey U, Strehl J, Zinske C, Schepke M, Schmid F, Wolf IG, Sauerbruch T, Glasmacher A, et al. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol. 2005;75(1):1–13.
  4. Williams N, Scott AD. Neutropaenic enterocolitis : a continuing surgical challenge. Br J Surg. 1997;84(9):1200–1205.